Lantheus 2021 results, 2022 outlook

 Outlook

The Company updates its guidance for the first quarter and full year 2022 is as follows:

		Guidance Issued February 24, 2022
Q1 FY 2022 Revenue		$160 million - $170 million
Q1 FY 2022 Adjusted Fully Diluted EPS		$0.45 - $0.50
		Guidance Issued February 24, 2022
FY 2022 Revenue		$685 million - $710 million
FY 2022 Adjusted Fully Diluted EPS		$1.95 - $2.05

On a forward-looking basis, the Company does not provide GAAP income per common share guidance or a reconciliation of adjusted fully diluted EPS to GAAP income per common share because the Company is unable to predict with reasonable certainty business development and acquisition related expenses, purchase accounting fair value adjustments (including liability accruals relating to the contingent value rights issued as part of the Progenics Pharmaceuticals, Inc. acquisition), and any one-time, non-recurring charges. These items are uncertain, depend on various factors, and could be material to results computed in accordance with GAAP. As a result, it is the Company’s view that a quantitative reconciliation of adjusted fully diluted EPS on a forward-looking basis is not available without unreasonable effort.

https://finance.yahoo.com/news/lantheus-holdings-inc-reports-fourth-120000655.html